Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Decline in Short Interest

Propanc Biopharma Inc (NASDAQ:PPCB) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 20,152 shares, a drop of 84.9% from the July 15th total of 133,524 shares. Based on an average trading volume of 99,223 shares, the short-interest ratio is presently 0.2 days. Currently, 1.2% of the company’s shares are short sold.

Propanc Biopharma Stock Up 4.3%

Shares of NASDAQ:PPCB traded up $0.05 during trading on Wednesday, reaching $1.22. 25,963 shares of the company’s stock traded hands, compared to its average volume of 1,667,111. The firm has a market cap of $2.78 million, a PE ratio of -0.05 and a beta of 3.52. Propanc Biopharma has a fifty-two week low of $0.95 and a fifty-two week high of $260.00. The company has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $2.85.

Propanc Biopharma announced that its Board of Directors has initiated a share repurchase program on Thursday, June 11th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 162.3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Propanc Biopharma in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Propanc Biopharma has an average rating of “Sell”.

Institutional Trading of Propanc Biopharma

A hedge fund recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC acquired a new position in shares of Propanc Biopharma Inc (NASDAQ:PPCB) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma as of its most recent filing with the SEC.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.